Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
PR Newswire•10/11/2026•06:45 ET
0
Key Highlights
- ➤Nine-month revenue $75.6M, up $32.0M year to date
- ➤Nine-month net income $26.1M versus $1.1M loss in 2025
- ➤2026 revenue guidance reaffirmed at approximately $78.0M-$83.0M
- ➤PRX-115 RELEASE Phase 2 top-line results expected in second half of 2027
- ➤Cash, cash equivalents, and short-term deposits totaled $48.5M
Expert Statements
Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics
“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities”
Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics
“We end the quarter with cash and deposits of $48.5 million, a position of strength that enables us to continue advancing PRX–115 for uncontrolled gout.”
Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics
“Uncontrolled gout is a disease with low quality of life and high unmet need and represents a blockbuster uricase market opportunity.”
Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics
“Current uricase therapy has challenges including infusion burden, immunogenicity with loss of efficacy, and safety concerns.”
Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics
“We designed PRX-115 for reduced immunogenicity and less frequent dosing that could reduce infusion burden and improve patient adherence.”
Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics
“We look forward to top-line results from the RELEASE study in the second half of 2027.”
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results PR Newswire
Company to host conference call and webcast today at 8:00 a.m. ET
Get started
Create a free account to read the full story.